Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

NCT01431547 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: dalotuzumab
DRUG: dalotuzumab
DRUG: ridaforolimus

Sponsor

Merck Sharp & Dohme LLC